– Annual survey has ranked Alnylam within the top five on the best employers list since 2019 –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ranked third in Science’s 2021 Top Employers Survey. The magazine’s annual survey of more than 7,200 people in biotechnology, biopharmaceutical, pharmaceutical, and related industries determine the top 20 best employers, as well as reveals their driving characteristics. Alnylam’s 2021 ranking marks the third consecutive year that it has placed within the top five on the best employers list.
Survey respondents rated companies on attributes such as corporate image, leadership and direction, work culture/environment, and academic and intellectual challenge. According to Science, the 2021 global survey results were based on responses from North America (64 percent), Europe (19 percent) and the Asia/Pacific Rim (11 percent). This year’s survey focused on how companies help employees navigate the pandemic, and elements that empower employees for success.
“Results from Science’s annual Top Employers Survey attests to our belief that to bring breakthrough medicines to patients around the world, we must always anticipate, listen, and respond to the needs of employees. We pride ourselves on a culture that values transparency and diversity of thought, just as much as innovation, and are incredibly humbled by the continued recognition of Alnylam as a special place to work,” said Kevin Fitzgerald, Ph.D., Chief Scientific Officer of Alnylam. “By empowering employees to accept new challenges, we affirm our commitment to patients, world-class science, and becoming a top-5 biotech in the next five years.”
Alnylam's top attributes, from among five scored by Science included, “Innovative leaders in the industry”; “Treats employees with respect”; and “Is socially responsible”.
For the complete feature and company rankings, please visit: https://www.sciencecareers.org/TopEmployers2021
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran), as well as Leqvio® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.
Alnylam Pharmaceuticals, Inc.
Christine Regan Lindenboom
(Investors and Media)